Business Wire

AlgoTx Raises €20M to Conduct ATX01’s Phase 2 Program in Peripheral Neuropathic Pain


European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), announced today the success of a €20M Series B fundraising led by Relyens Innovation Santé / Turenne Capital , followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital. Early and new business angel investors also significantly participated in this financing round, and AlgoTx secured an additional 1M€ in non-dilutive financing. The proceeds will be used to demonstrate the clinical efficacy of ATX01 in neuropathic pain.

Bervin Bouani, Investment Director at Turenne Capital, commented: “We are very proud to lead this strategic financing round to support AlgoTx to continue the clinical development of ATX01 lead candidate that has the potential to significantly improve the lives of patients with neuropathic pain. We look forward to working with Stéphane and his outstanding team to transform AlgoTx into a global pain player.”

Following the demonstration of ATX01’s early clinical safety and low systemic passage in Phase 1, the Phase 2 “ACT” study will now assess ATX01’s ability to reduce pain in adult CIPN patients – a program granted “fast-track” designation by FDA. In parallel, the Phase 2 “EASE” study will explore ATX01’s efficacy in the debilitating pain of erythromelalgia, a program for which ATX01 was granted “Orphan Disease Designation” in the US and Europe.

Stéphane Thiroloix, Founder & CEO of AlgoTx, says: “It is incredibly exciting to start the efficacy trials of ATX01, supported by such a high-profile syndicate of investors. We look forward to enrolling patients in our studies any day now.”

Over half of cancer patients treated with chemotherapy develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. It affects over two million patients in the US and Europe and represents a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists, neurologists and pain specialists.

« We are very pleased to support the AlgoTx team in the development of ATX01, driven by our belief in its significant impact in the treatment of CIPN and other neuropathic pain. AlgoTx can truly transform the lives of patients suffering from these conditions », says Pauline de Breteuil Senior Partner UI Investissement / FCPI Majycc Innovation Santé.

About AlgoTx
AlgoTx develops novel treatments for complex pain, with lead program ATX01 in Phase 2 in chemotherapy-induced peripheral neuropathy (NCT05593614) and erythromelalgia. More information at
ACT study : ATX01 for the pain of ChemoTherapy, (NCT05593614). EASE study : Efficacy of ATX01 / Study in Erythromelalgia.

Launched in 2014, Relyens Innovation Santé is is an evergreen venture capital vehicle specializing in health innovation controlled and owned by Relyens, a mutual insurance company specializing in the risk management of health, social and medical players. Relyens is the leading French player in medical civil liability. Advised by Turenne Santé (Health Division of Turenne Group), Relyens Innovation Santé's mission is to support the growth and development phases of innovative companies in the health sector.
Turenne Group, one of the leading private equity companies in France, has been supporting entrepreneurs for 23 years in their company’s innovation, development and transfer projects. As an independent player, the Group has assets of €1.4 billion under management. Its teams, made up of 68 professionals, including 52 investors, based in Paris, Lille (Nord Capital Partenaires), Lyon, Bordeaux, Marseille, Nice and Metz, support 290 business leaders, particularly in the healthcare, hospitality, innovation, BtoB services, and in the digital and impact sectors. With more than €300m, our healthcare team (Turenne Santé) invests across the entire value creation chain for healthcare companies through various investment approaches.
For more information: /

About Bpifrance and InnoBio 2
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export).
InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS, European Investment Fund and Pasteur Mutualité. InnoBio 2, with €203 million, aims to invest in companies developing innovative products and services, close to or in early clinical development, with the objective of bringing them until the clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds.
For more information, please visit: – Follow us on Twitter : @bpifrance - @BpifrancePresse

About Omnes
Omnes is a leading Paris-based European investor in private equity and infrastructure. With more than €5 billion in assets under management, Omnes provides companies with the equity capital they need to grow through its four core businesses: Venture Capital, Buyout & Growth Capital, Infrastructure and Co-Investment. With more than 30 trade sales and nearly 15 IPOs in 20 years (including Themis Bioscience, Biovex, arGEN-X, Novaled and Direct Energie), Omnes Venture Capital team is a leading French player in financing innovative SMEs with dual expertise in the deep-tech and healthcare sectors. Omnes is committed to ESG issues and has set up the Omnes Foundation in aid of children’s charities. The company is also a signatory to the United Nations Principles for Responsible Investment (PRI).

About UI Investissement
UI Investissement is an independent, specialized company in the development of unlisted French companies with €1.5 billion under management. For over 50 years, UI Investissement has been committed to work alongside the managers of growing SMEs and STIs to help them emerge as economically and sustainably successful businesses through its focus on three areas: health, agro-business, and business services.
With its expertise, UI Investissement provides support to companies in the health sector at all stages of their development and plays a central role in the ecosystem. It is through the Majycc Innovation Santé fund that UI Investissement supports entrepreneurs who aim to be the architects of tomorrow's health. The roots of Majycc Innovation Santé are deeply connected to the DNA of several private clinic groups, nursing home groups, and mutual health insurance companies, representing entrepreneurship, health and human values, respect for corporate culture, and the projects of the individuals who build them.

To view this piece of content from, please give your consent at the top of this page.

Contact information

AlgoTx : Geneviève Cliquet Consultant : 607 500 567
Turenne Capital : Sandra Capela: ; Agence TADEO, Louis Branger - 06 76 23 52 85
Bpifrance : Juliette Fontanillas :
Omnes Capital: Yanie de Nadaillac : - +33(0) 7 63 13 65 74
UI Investissement : Laurent Maillard

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SimCorp Unites with FlexTrade to Add New EMS Ecosystem Partner28.3.2023 09:02:00 CEST | Press release

SimCorp, an independent provider of investment management solutions, has partnered with FlexTrade Systems, a global leader in high-performance multi-asset trade execution management systems (EMS), to extend SimCorp's Order Management System (OMS) capabilities by incorporating the cross-asset EMS functionality of FlexTrade's FlexTRADER EMS. This partnership addresses the increasing demand from trading teams for seamless integration and collaborative workflows between their OMS and EMS solutions. The integration will help optimize trading activities and assist in meeting best execution obligations. As part of the partnership, FlexTrade will join SimCorp's Open Platform program. The Open Platform program is designed to offer its client base frictionless access to innovative fintech solutions across the investment value chain. A key component of the new agreement will see the two firms work together to deliver enhanced, seamless connectivity between SimCorp's OMS, Order Manager, and FlexTr

euNetworks Forms Exclusive Partnership on CrossChannel Fibre System to Deliver Ultra-Low Latency Services Between London and Madrid28.3.2023 09:00:00 CEST | Press release

euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has entered into an exclusive partnership agreement with Crosslake Fibre UK Limited (“Crosslake”), an international network provider and developer of unique subsea and terrestrial fibre networks. This partnership relates to Crosslake’s new CrossChannel Fibre system and gives euNetworks exclusivity to deliver ultra-low latency services between the United Kingdom and Madrid on this system to the financial services community. euNetworks has also agreed to a strategic relationship, enabling the sale of dark fibre services by euNetworks using the system. This press release features multimedia. View the full release here: Paula Cogan, CEO of euNetworks (Photo: Business Wire) CrossChannel Fibre is a 550km cable system with end-to-end fibre running between Slough, United Kingdom and Paris, France and is the first subsea

Adva Network Security protects TransnetBW’s communication network28.3.2023 09:00:00 CEST | Press release

Adva Network Security today announced that TransnetBW has deployed its ConnectGuard™ encryption technology with the Adtran FSP 3000 optical transport solution to establish a highly secure communication network in its service area. As the operator of an electricity transmission grid in southwestern Germany and a European interconnection partner, TransnetBW depends on the security and reliability of its communication network to ensure trouble-free operations. That’s why the company chose the FSP 3000 optical platform with Adva Network Security encryption technology, which has been approved by the German Federal Office for Information Security (BSI). This solution enables high-speed connections to be reliably and robustly protected, even against sophisticated cyberattacks. Planning and implementation of the highly secure infrastructure were carried out by Adva Network Security’s long-standing partner Syserso Networks, who will also provide ongoing support. This press release features mult

Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse ® G NfL CSF and Lumipulse ® G NfL Blood tests28.3.2023 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE® G immunoassay systems. These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of Neurofilament light (NfL) in human Cerebrospinal fluid (CSF) and plasma/serum, respectively, within just 35 minutes. The two assays are available for Research Use Only. “In 2022, we introduced three fully automated blood-based assays for the detection of pTau181, β-Amyloid1-42 and β-Amyloid1-40, and we are now proud to once again expand our neurodegenerative disease portfolio with the highly anticipated NfL biomarker,” Christiaan De Wilde, CEO of Fujirebio Europe and Global Head Neuro Business. “The assay menu offered by other industry leaders today is still limited and we are working diligently to create a solid lineup of tests for the entire neurodegenerative

Sofinnova Partners Launches Digital Medicine Strategy28.3.2023 06:00:00 CEST | Press release

Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced today that it has launched a new investment strategy focused on digital medicine. The strategy will be headed by Partners Edward Kliphuis and Simon Turner, who bring over a decade of experience investing in startups at the intersection of biology, data, and computation. This press release features multimedia. View the full release here: Edward Kliphuis (left) and Simon Turner (right) (Photo: Business Wire) Sofinnova Digital Medicine will back entrepreneurs innovating at the cutting edge of technology and biology and help them scale to become global leaders. Like all the funds on Sofinnova’s platform, Sofinnova Digital Medicine will focus on developing the most promising innovations that address systemic challenges in healthcare and can profoundly improve the lives of patients worldwide. Antoine Pap